Qiagen (NASDAQ:QGEN – Get Rating) is one of 283 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Qiagen to similar companies based on the strength of its analyst recommendations, institutional ownership, profitability, risk, valuation, dividends and earnings.
Profitability
This table compares Qiagen and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Qiagen | 19.76% | 16.45% | 8.71% |
| Qiagen Competitors | -4,262.95% | -141.31% | -40.13% |
Earnings and Valuation
This table compares Qiagen and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Qiagen | $2.14 billion | $423.21 million | 24.99 |
| Qiagen Competitors | $716.87 million | $90.45 million | -2.64 |
Volatility & Risk
Qiagen has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Qiagen’s peers have a beta of 0.94, indicating that their average share price is 6% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Qiagen and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Qiagen | 0 | 0 | 0 | 0 | N/A |
| Qiagen Competitors | 1011 | 4048 | 11101 | 170 | 2.64 |
As a group, “Biological products, except diagnostic” companies have a potential upside of 76.42%. Given Qiagen’s peers higher probable upside, analysts clearly believe Qiagen has less favorable growth aspects than its peers.
Institutional and Insider Ownership
58.6% of Qiagen shares are held by institutional investors. Comparatively, 46.5% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 15.9% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Qiagen beats its peers on 7 of the 10 factors compared.
About Qiagen
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
